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Meta-analysis of outcome studies in end-stage renal disease. interest. Meta-analysis has proven to be a valuable tool
Studies examining outcomes in patients with ESRD are derived in many areas of contention in clinical medicine. Its suc-
from a variety of sources (single center, regional registries,
cess lies in its ability as an approach to harmonize appar-national registries, etc.) and provide discrepant results as to
ently conflicting findings by application of data poolingthe impact of modality selection on patient survival. In an
attempt to understand and resolve these discrepancies, an ex- and systematized study weighting. The success of meta-
haustive literature search and meta-analysis were performed to analysis, however, is dependent on the inherent values of
compare survival in hemodialysis (HD) and peritoneal dialysis
published data, the potential comparability of available(PD) patients using published data from both registry studies
studies, and the level of required detail in the existingand non-registry studies. Results of the meta-analysis, based
on data from 82 literature non-registry studies, 55 literature literature. In a sense, meta-analysis can be viewed as a
registry studies, and two registry reports, censored for modality critical analysis tool that not only enlightens by determin-switches, transplants and dropouts and unadjusted for case
ing validity of concepts or views, but also by uncoveringmix, were inconclusive because survival and mortality out-
comes varied with the data sources and formats for outcomes the merits or demerits of existing literature. In an attempt
analyzed. Although limited data suggested that differences in to resolve the discrepancies in patient outcomes reported
case mix may contribute to differences in survival outcomes, in ESRD, a meta-analysis was performed to compareadjustments for case mix (predialysis comorbid conditions),
survival in peritoneal dialysis (PD) and hemodialysisadequacy of dialysis, and other important patient level covari-
ates were not possible because of the paucity of available data. (HD) patients, adjusting for case mix where data permit,
These findings highlight the limitations inherent in current using published data from both registry studies and non-
literature reports and underscore the need for more uniform,
registry studies.standardized, and detailed approaches than has hitherto been
the case in reporting outcome findings in ESRD.
METHODS
Studies examining outcomes in patients with end-stage This study employed techniques for meta-analysis that
renal disease (ESRD) are derived from a variety of represent the latest in the evolving science of review
sources (single center, regional registries, national regis- research [12–14]. Briefly, a study protocol was designed
tries, etc.) and provide discrepant results as to the impact prospectively to define the study objectives, eligibility
of modality selection on patient survival. These reports criteria for inclusion of trials, key data elements to be
vary in their patient numbers (single center vs. national extracted, and analytical methods to be employed. Data
registries), patient group selection (point prevalent vs. extraction forms were designed and tested prior to imple-
period prevalent vs. incident), methods of data acquisi- mentation. Published studies were selected and data ex-
tion (governmental agencies, chart reviews, voluntary tracted by two reviewers (one physician and one research
reporting), statistical approaches (as-treated vs. intent-
analyst) working independently; data extraction formsto-treat), and adjustment for relevant variables that are
were checked against one another and differences wereknown or expected to affect survival (comorbidity, ade-
resolved by referring to the original papers. Registryquacy, etc.) [1–11]. Additionally, a historical prospective
data were extracted by a single reviewer and checkedapproach has been used by the United States Renal Data
back against the tables in the registries from which theSystem (USRDS). This approach simulates a prospective
data were extracted. Data from the data extraction formsstudy as it selects a historical start date and then is
were entered into Excel spreadsheets for subsequentblinded to subsequent events to evaluate outcomes of
storage in a customized relational database. Prior to lock-
ing the data set for statistical analysis, 100% verification
was performed. 2000 by the International Society of Nephrology
S-28
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Study selection median and actuarial one- and five-year survival data
(percentage alive per year of follow-up) or from Kaplan-Studies were identified by a MEDLARS search using
Meier survival curves. Mortality outcomes were reportedthe search terms “dialysis,” “hemodialysis” or “perito-
either as gross mortality rates or as deaths adjusted forneal dialysis,” and human trials (including epidemiology
extent and duration of dialysis exposure (e.g., deathsstudies); all years from 1980 through August 1997 and
per 100 patient-years). Survival outcomes almost alwaysEnglish, Spanish, French, German, and Italian languages
were censored for modality switches, transplants, andwere included. In order to capture very recent publica-
dropouts, and unadjusted for case mix. When adjustedtions, the CD-ROM version of Current Contentst also
for case mix, the adjusted survivals also were captured.was searched. Computer-based searches were supple-
The prevalence cohort was the cohort most often re-mented by manual searching of bibliographies of re-
ported (or assumed) and consequently was the cohorttrieved papers to detect other potentially acceptable
selected for the meta-analysis, with few exceptions: stud-studies. Additionally, registry reports were examined.
ies based on the USRDS registry used either incidentAll retrieved abstracts and studies were screened initially
or point-prevalent cohorts, and the Australia and Newto exclude studies that were clearly ineligible, such as
Zealand Combined Dialysis and Transplant Registryanimal studies, metabolic or surgical studies, or short-
(ANZDATA) registry provided patient denominatorsterm studies of dialysis solutions or techniques without
on both incident and prevalent populations. Start timesurvival outcomes.
for survival measurement in the literature non-registry
studies usually was the start of dialysis but in analysesData extraction
derived from registries it varied, introducing a systematicKey data elements extracted from each study included
difference of up to three months. From each source ofstudy characteristics; patient and treatment characteris-
data, only data from dialysis-only patients were analyzed,tics; and clinical outcomes of interest. Study characteris-
not the results for all ESRD patients, which invariablytics included the publication date, language, geographic
included a large number of patients undergoing renallocation, data source (registry/non-registry), patient ac-
transplantation.
crual and follow-up periods, study design (observational/
Survival results were combined from meta-analysis us-
interventional, prospective/retrospective, and random-
ing both fixed (FEM) and random effects models (REM),
ized controlled trial or not), the number of patients on with outcomes expressed as odd ratios (OR) or risk dif-
HD and PD and, if specified, center or home treatment ferences (RD), with 95% confidence intervals (95% CI).
location. Patient characteristics included age, gender, The natural logarithm of these ratios was used to satisfy
race, mean duration of ESRD (or dialysis), and number the assumptions of normality [15, 16].
or percentage of patients with diabetes and hypertension. The FEM [17, 18] assumes that the studies have a
Treatment characteristics included the dialyzer type, fre- common mean and variance and uses pooled data. This
quency, and time per dialysis for HD and the exchange model essentially computes the pooled estimate as a
volume, and number of exchanges per day for PD; addi- weighted average of the individual study estimates, each
tionally, the number or percentage of patients receiving weighted by the inverse of the study variance. By assum-
ancillary erythropoietin and blood transfusions was ex- ing that this estimate follows a normal distribution, a
tracted. Efficacy outcomes of interest were median and confidence interval can be computed in the usual manner
actuarial survival rates and overall and annual mortality with the standard error of the weighted average.
rates; the availability of extractable quality of life mea- The REM [15] assumes that each study has its own
sures and medical utilization measures also was noted. mean mi and variance si2 (i.e., that it follows its own
Descriptive tables were prepared that summarized the treatment effect distribution) but that the mi are drawn
characteristics of studies, study populations, and out- from a superpopulation of treatment effects with its own
comes. For many studies, the characteristics of study mean m and variance t2 which describes the between-
populations and/or outcomes of interest were available treatment heterogeneity. As in the FEM, m is estimated
for the total dialysis (or ESRD) population, but not for by a weighted average of the study effects, but in the
subgroups on HD and PD. REM the weights, 1/(t2 1 Ssi2), are the inverses of the
sums of the within-study variance si2 and the between-
Statistical analysis study variance t2. When t2 5 0 so that the treatment
The main hypothesis tested was that survival of ESRD effects mi are all the same, the REM 5 FEM and the
patients receiving PD is comparable to that of patients DerSimonian and Laird estimate of t2 [15] is used in the
receiving HD when prognostic factors are adjusted. weighting formula. Because of the different weighting,
However, hypothesis testing was confounded because larger studies have less effect on the REM estimate than
measurement and reporting techniques varied among on the FEM estimate. Confidence intervals generally are
wide in the REM because estimates of variance are largerthe studies. Survival outcomes were taken from reported
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Table 1. Study characteristicsdue to the inclusion of t2. The REM usually provides a
more conservative estimate, and is particularly useful to Literature Literature
non-registry registrycheck the robustness of a significant result obtained using
Total studies 82 55the FEM. However, the FEM gives a result that is not
Total patients on study 32,648 1,599,501significant, the REM usually will not provide additional
261 19,747
information. Mean number of patients, range (9–4,083) (70–341,902)
Geographic locationaIndependent variables in the analysis were type of
Europe 44% 36%dialysis, HD or PD. Covariates of interest identified a
USA 35% 36%
priori were data source, geographic location, observation Canada 6% 9%
Japan 2% 7%interval, patient age, race, gender, duration of ESRD
South America 6% 2%(or dialysis), diabetes, hypertension, dialysis type and
Australia/New Zealand 1% 5%
features thereof, including dialysis prescription and dial- Multi-centric 1% 4%
Other 4% 0ysis dose delivered, and the use of erythropoietin and
Publication datesablood transfusions.
1988 or earlier 23% 16%
Multivariate regression analyses were planned to ad- After 1988 77% 84%
Languageajust survival for prognostic factors. Subgroup analyses
English 90% 98%also were planned, as data permitted, for gender, age,
French 4% 0
race, hypertension, and diabetes. Homogeneity of stud- Other 5% 2%
Study designaies was tested using Cochran’s Q statistic. All calculations
Retrospective observational 72% 95%were performed using SASt software version 6.11.
Prospective observational 22% 5%
Prospective interventional 6% 0
a Values are given as percent of all studies.RESULTS
Study characteristics
A total of 4289 citations were retrieved from MED-
LARS (3936), Current Contentst (133) and manual France; European Dialysis and Transplant Association
European Renal Association (EDTA-ERA); Italian Co-searches of bibliographies (220). Of these, 360 publica-
tions passed the first screen and 137 studies (146 publica- operative Peritoneal Dialysis Study Group (ICPDSG);
Japanese Society for Dialysis Therapy (JSDT); Piedmonttions) satisfied all criteria for eligibility. The main reasons
for study ineligibility at second screening were no sur- Registry; Lombardy Regional Dialysis and Transplant
Registry; Hemodialysis National Register (HDNR) ofvival outcomes (160); literature reviews and commentaries
(21); technique assessments (14); outcomes not extract- Uruguay; Michigan Kidney Registry (MKR); Okinawa
Dialysis Study (ODS); Romanian Renal Registry; Re-able or entire population (10); only certain sub-groups
not of interest for this analysis, such as lupus patients, gional Registry of Dialysis and Transplantation (RPDT)
of Europe; Toronto Region Dialysis Registry (TRDR);patients with congestive heart failure, or pediatric pa-
tients (6); and ineligible language (3). Characteristics of USA National CAPD Registry (USANCAPDR) and
US Continuous Ambulatory Peritoneal Dialysis Registrythe studies included in the meta-analysis are summarized
in Table 1. (USCAPDR).
Of the 137 eligible studies, most were published in
Patient and treatment characteristicsthe English language after 1988 and were retrospective
observational designs. There were only five prospective Survival for ESRD patients receiving HD was assessed
in 39 literature non-registry studies, 24 literature registryinterventional studies, none of which were randomized
controlled trials. Data from three categories of stud- studies, and the CORR and ANZDATA registries. Sur-
vival for ESRD patients receiving PD was assessed inies—82 literature non-registry studies (Appendix 1, typi-
cally a single dialysis center or network of such centers), 48 literature non-registry studies, 24 literature registry
studies, and the CORR and ANZDATA registries. Only55 literature registry studies (Appendix 2), and three
registry reports (USRDS; Canadian Organ Replacement 5 literature non-registry studies and the CORR and
ANZDATA registries assessed both types of dialysis.Register [CORR]; and ANZDATA)—were analyzed
both separately and together, when appropriate to the Both the literature non-registry and registry studies
(Table 2) were comparable in the mean duration ofanalysis of survival. Registries represented in the litera-
ture registry studies included the USRDS and certain of ESRD or dialysis at study entry (2.04 and 2.57 years,
respectively) and mean follow-up time on dialysis (5.8its Networks; ANZDATA; Andalusia Renal Patients
Registry (ARPR); CAPD Cooperative Study Group of and 5.9 years, respectively). Information on case mix was
not consistently available. Among those studies re-Italy (CAPDCSGI); CORR; Canadian Renal Failure
Registry (CRFR); Diaphene Dialysis Registry (DDR) of porting case mix, there was a substantial difference be-
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Table 2. Patient characteristics studies involving 8352 patients) and the mean volume
per exchange was 2 L (reported in 31 studies involvingLiterature Literature
non-registry registry 8091 patients). Several studies referred to the fact that
Total studies 82 55 CAPD outcomes improved after initial introduction of
Total patients on study 32,648 1,599,501 the technique in the early to mid 1980s due to increased
Mean duration of ESRD/dialysis
experience and the introduction of improved dialysisat study entry, years 2.04 2.57
Mean duration of follow-up, years 5.8 5.9 solutions delivery systems. Many studies also mentioned
Studies reporting case mix specific referral rules for patients to PD vs. HD. How-% Patients with diabetes 21 25
ever, local referral patterns different markedly, with the% Patients with hypertension 37 15
Number of studies reporting race 9 (11%) 14 (25%) “sickest” and/or oldest patients in some regions prefer-
Number of patients (% total) 2,205 (7%) 270,410 (17%) entially referred to PD, while in other regions those% Caucasian 47 64
“sickest” and/or oldest patients were preferentially of-% African-American 48 32
% Other 5 4 fered HD.
Survival outcomes
Crude death rates were calculated as total number ofTable 3. Treatment characteristics
deaths divided by total patients at risk for any time inter-
Literature Literature val (usually annual) and, where available, for patient
non-registry registry
subgroups of interest. Within each category of studies,
Total studies 82 55 survival results from studies with both an HD and PDTotal patients on study 32,648 1,599,501
group were combined for a meta-analysis using bothStudies reporting HD (% total) 39 (48%) 24 (44%)
Number of patients (% total) 8,621 (26%) 387,579 (24%) fixed (FEM) and random effects models (REM), with
Mean HD frequency per week,
outcomes expressed as odds ratios (OR) or risk differ-post-1986 2.8 2.7
Mean time per dialysis, post-1986 11.3 h 11.3 h ences (RD). Meaningful subgroup analyses could not be
Studies reporting PD (% total) 48 (59%) 24 (44%) performed because too few studies provided survival
Number of patients (% total) 6,740 (21%) 76,245 (5%)
information on HD and PD patients with diabetes (oneMean PD frequency per day
Pre-1986 4.0 not reported non-registry and three registry studies and ANZDATA
Post-1986 4.3 not reported registry) and hypertension (no studies), patients older
than 60 or 65 (one non-registry and one registry study),
or various racial or gender groups (one or fewer studies).
Results of the meta-analysis using unadjusted data,tween the non-registry and registry studies (37% vs. 15%
summarized in Table 4 and Table 5, were inconclusivepatients with hypertension in literature non-registry and
because survival and mortality outcomes varied with theregistry studies, respectively). Representation of the two
data sources and outcomes analyzed. Odds ratios andmodalities was different between the two types of re-
risk differences for death computed for the various cate-ports. Literature registry studies reported on only a very
gories of studies, using unadjusted data, showed a greatersmall percentage of patients receiving PD (21% vs. 5%
likelihood of deaths in the HD group (OR . 1 and RD .of patients in non-registry and registry studies, respec-
0) for the literature non-registry studies (N 5 10) and thetively).
CORR registry report but greater likelihood of deaths inIn both the non-registry and registry studies (Table
the PD group (OR , 1 and RD , 0) for the literature3) reporting on patients receiving HD, the number of
registry studies (N 5 4) and ANZDATA registry report.sessions per week per patient (2.8 and 2.7, respectively)
Results were statistically significant for both the litera-and mean time on dialysis per week (11.3 and 11.3 hours,
ture non-registry studies and CORR registry report usingrespectively) were comparable; registry reports did not
the FEM model and for the literature non-registry stud-report this level of detail. There was little different be-
ies using the REM model.tween studies published before or after 1986. The dialysis
Odds ratios and risk differences for one-year survivalprescription and dose delivered were reported too infre-
computed for the literature non-registry (N 5 11) andquently and too inconsistently to be analyzable.
literature registry studies (N 5 5), using unadjusted data,In the non-registry studies reporting on patients re-
showed a survival benefit in the PD group (OR , 1 andceiving PD (Table 3), the majority of cases involved
RD , 0) in both categories of studies. In contrast, oddschronic ambulatory peritoneal dialysis (CAPD). Inter-
ratios and risk differences for five-year survival, whichmittent peritoneal dialysis (IPD) and chronic cyclic peri-
could be computed only for literature registry studiestoneal dialysis (CCPD) were reported separately so in-
(N 5 4), showed a significant survival benefit for HDfrequently as to be negligible in the data set. The mean
number of exchanges per day was 4.3 (reported in 32 (OR . 1, RD . 0). No useful data were obtained from
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Table 4. Meta-analysis of unadjusted death and survival rates for HD and PD
HD PD
FEM REM FEM REM
N overall (95% CI) overall (95% CI) N overall (95% CI) overall (95% CI)
Death rate
Non-registry 26 43% (42, 44) 30% (15, 46) 33 43% (42, 44) 32% (17, 46)
Registry 7 10.3% (10.2, 10.4) 18.3% (15, 21) 6 13% (12, 13) 16% (12, 19)
ANZDATA 5 10.8% (10.5, 11.2) 11% (8, 13) 5 16.5% (15, 17) 16% (15, 17)
CORR 11 18% (18, 19) 18% (17, 19) 11 18% (17, 18) 18% (17, 19)
1-year survival rate
Non-registry 18 84% (83, 85) 81% (75, 86) 24 88% (87, 89) 85% (81, 88)
Registry 7 86% (85, 87) 87% (83, 90) 11 84.6% (84, 85) 85.8% (84, 90)
5-year survival rate
Non-registry 13 58% (56, 60) 58% (51, 66) 9 34% (32, 36) 49% (31, 67)
Registry 5 45% (44, 46) 47% (32, 63) 7 42% (41, 43) 40% (30, 50)
Abbreviations are: FEM, fixed effects model, REM, random effects model.
Table 5. Meta-analysis for odds and risk of survival outcomes for HD vs. PD using unadjusted rates
FEM REM
N Overall 95% CI P value Overall 95% CI P value
OR (death)
Non-registry 10 1.23 (0.98, 1.54) 0.06 1.23 (0.98, 1.55) 0.07
Registry 4 0.92 (0.88, 0.95) 0.0 0.93 (0.77, 1.14) 0.50
ANZDATA 5 0.63 (0.60, 0.66) 0.0 0.60 (0.46, 0.80) 0.0
CORR 11 1.14 (1.08, 2.16) 0.03 1.0 (0.89, 1.13) 0.89
RD (death)
Non-registry 11 0.036 (0.009, 0.062) 0.008 0.036 (0.009, 0.062) 0.008
Registry 4 20.01 (20.015, 20.007) 0.0 20.001 (20.022, 0.019) 0.89
ANZDATA 5 20.05 (20.06, 20.04) 0.0 20.05 (20.08, 20.02) 0.0
CORR 11 0.007 (0.002, 0.013) 0.01 0.001 (20.016, 0.019) 0.88
OR (1-year survival)
Non-registry 11 0.89 (0.71, 1.12) 0.33 0.88 (0.62, 1.25) 0.48
Registry 5 0.81 (0.74, 0.89) 0.0 0.96 (0.64, 1.43) 0.83
RD (1-year survival)
Non-registry 11 20.03 (20.053, 20.009) 0.006 20.01 (20.058, 0.036) 0.65
Registry 5 20.023 (20.034, 20.014) 0.0 20.007 (20.056, 0.041) 0.76
OR (5-year survival)
Non-registry 0
Registry 4 1.48 (1.38, 1.58) 0.0 1.73 (1.06, 2.82) 0.02
RD (5-year survival)
Non-registry 0
Registry 4 0.09 (20.077, 0.106) 0.0 0.12 (0.009, 0.230) 0.03
When odds ratio (OR) for death is .1, odds of death in HD is higher than PD; when odds ratio (OR) for survival is .1, odds of survival in HD is higher than
PD; when risk difference (RD) for death is .0, risk of death in HD is higher than PD; when risk difference (RD) for survival is .0, survival in HD is higher than PD.
Abbreviations are: FEM, fixed effects model, REM, random effects model.
the USRDS registry report since survival outcomes by (20.176, 20.064)]; unfortunately, data were not avail-
type of dialysis were not presented. able to compute adjusted results for literature registry
Limited data suggested that differences in case mix studies. An analysis of the subgroup of dialysis patients
may contribute in large part to the observed differences with diabetes, which was possible only with the literature
in survival outcomes (Table 6 and Table 7). For example, registry data, showed that diabetics had reduced survival
while literature non-registry studies using unadjusted compared with nondiabetics, regardless of the type of
data showed a significant survival advantage for patients dialysis used.
receiving PD [meta-analysis based on 3 studies gave OR
(death) 5 (0.98, 1.54) and meta-analysis based on 11
DISCUSSIONstudies gave RD (death) 5 0.036 (0.009, 0.062)], the
This meta-analysis of 82 literature non-registry studiesopposite result was obtained using data adjusted for
(Appendix 1), 55 literature registry studies (Appendixcase mix [meta-analysis based on 3 studies gave OR
(death) 5 0.53 (0.40, 0.71) and RD (death) 5 20.119 2), and registry reports from the US (USRDS), Canada
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Table 6. Meta-analysis of adjusted death and survival rates for HD and PD
HD PD
FEM overall REM overall FEM overall REM overall
N (95% CI) (95% CI) N (95% CI) (95% CI)
Death rate
Non-registry 3 20% (17, 24) 21% (9, 33) 4 29% (26, 33) 29% (19, 39)
Registry 1 52% (50, 54) 52% (50, 54) 0
ANZDATA 0
CORR 0
1-year survival rate
Non-registry 3 94% (92, 96) 94% (92, 96) 4 94% (92, 96) 90% (84, 96)
Registry 0 0
5-year survival rate
Non-registry 2 71% (67, 75) 70% (62, 78) 2 58% (53, 63) 54% (38, 71)
Registry 0 0
Abbreviations are: FEM, fixed effects model, REM, random effects model.
Table 7. Meta-analysis for odds and risk of survival outcomes for HD vs. PD using adjusted rates
FEM REM
N Overall 95% CI P value Overall 95% CI P value
OR (death)
Non-registry 3 0.53 (0.40, 0.71) 0.53 (0.40, 0.71)
Registry 0
ANZDATA 0
CORR 0
RD (death)
Non-registry 3 20.119 (20.176, 20.064) 20.119 (20.17, 20.06)
Registry 0
ANZDATA 0
CORRRR 0
OR (1-year survival)
Non-registry 3 1.05 (0.60, 1.82) 0.85 1.12 (0.52, 2.44) 0.75
Registry 0
RD (1-year survival)
Non-registry 3 20.002 (20.033, 0.028) 0.88 0.008 (20.041, 0.058) 0.74
Registry 0
OR (5-year survival)
Non-registry 2 1.85 (1.38, 2.47) 0.0 1.85 (1.38, 2.47) 0.0
Registry
RD (5-year survival)
Non-registry 2 0.13 (0.07, 0.19) 0.0 0.14 (0.058, 0.228) 0.001
Registry
When odds ratio (OR) for death is .1, odds of death in HD is higher than PD; when odds ratio (OR) for survival is .1, odds of survival in HD is higher than
PD; when risk difference (RD) for death is .0, risk of death in HD is higher than PD; when risk difference (RD) for survival is .0, survival in HD is higher than PD.
Abbreviations are: FEM, fixed effects model, REM, random effects model.
(CORR), and Australia/New Zealand (ANZDATA) differences for death computed using unadjusted data
from the literature registry studies (N 5 4) and thewas unable to resolve the question of whether PD and
HD provide equivalent survival outcomes for ESRD pa- ANZDATA registry report and by odds ratios and risk
differences for five-year survival which could be com-tients because results varied with the data sources and
outcomes analyzed. A survival benefit in the PD group puted only from unadjusted literature registry data
(N 5 4).was indicated by odds ratios and risk differences for
death computed using unadjusted data from the litera-
Limitations of data setsture non-registry studies (N 5 10) and the CORR regis-
try report and by odds ratios and risk differences for This meta-analysis suffered from several limitations
in the data sets analyzed.one-year survival computed using unadjusted data from
literature non-registry studies (N 5 11) and literature Limited reporting by type of dialysis. Most of the stud-
ies retrieved were not included in the meta-analysis be-registry studies (N 5 5). In contrast, a survival benefit
for the HD group was indicated by odds ratios and risk cause they reported only one type of dialysis, not both,
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or did not specify the type of dialysis at all. Notably, the in Canada obtained similar results using both a Poisson
model, which censored patients at the first switch andlargest data set available, the USRDS, did not report
survival outcomes by type of dialysis. Further, modality thereby assessed purely PD and purely HD, and a Cox
model, which assessed mixtures of PD and HD patients,representation in the available studies was highly vari-
able, reflecting different utilization patterns and practice suggesting that the bias reflected by technique failures
can be accounted for by proper analytic approaches.biases which may confound patient assignment and rep-
resentation in different modalities. The differences were
Potential for additional analysesmarkedly accentuated in several reports based on regis-
tries in which only a small percentage of patients were Given the limitations of the existing data sets in pub-
reported as receiving PD (21% vs. 5% of total patients lished reports, it is not clear whether additional analyses
receiving PD in literature non-registry vs. registry stud- might yield useful results. A meta-analysis of pooled
ies, respectively). treatment groups, which would include all HD and PD
Limited reporting on case mix. So few studies reported studies, not just those studies with both HD and PD
outcomes by important patient level covariates, such as groups, would benefit from the increased data available
concomitant diabetes or hypertension, age, gender, and for each of the treatment groups and increased informa-
race, that it was not possible to adjust for differences in tion on case mix. Although this approach would preclude
case mix or draw conclusions about outcomes in sub- within-study linkages that permit direct comparisons be-
groups of interest. Of interest, several studies have found tween treatment groups, since these were not random-
higher comorbidity prevalence in patients treated with ized, controlled studies, the loss of within-study linkages
PD compared with HD [2, 4, 8, 11]. In the one data may not be important. Additionally, in a pooled treat-
set where case mix could be examined, literature non- ment group analysis, stratifying the data by year of publi-
registry studies using unadjusted data showed a signifi- cation and by geographic location may allow an indirect
cant survival advantage for ESRD patients receiving PD estimate of the adequacy of dialysis, since methods and
[meta-analysis based on 10 studies gave OR (death) 5 techniques have changed at different times in different
1.23 (0.98, 1.54) and meta-analysis based on 11 studies regions. Logistic regressions of the stratified data and a
gave RD (death) 5 0.036 (0.009, 0.062)], but the opposite Bayesian inference of the year-stratified data also could
result was obtained using data adjusted for case mix be explored for further information.
[meta-analysis based on three studies gave OR (death) 5 Although limited data suggested that differences in
0.53 (0.40, 0.71) and RD (death) 5 20.119 (20.176, case mix may contribute to differences in survival out-
20.064)]. Results of the meta-analysis using adjusted comes, adjustments for case mix (predialysis comorbid
data were not consistent with findings from five pub- conditions), adequacy of dialysis, and other important
lished studies that found equivalent survival for ESRD patient-level covariates were not possible because of the
patients receiving PD and HD, analyzed using adjusted paucity of available data. These findings highlight the
data in the Cox proportional hazards model [2, 3, 5, 7, 11]. limitations inherent in current literature reports and un-
Limited reporting on adequacy of dialysis. The paucity derscore the need for more uniform, standardized, and
of data about the important features of dialysis pre- detailed approaches than has hitherto been the case in
scribed and delivered precluded an analysis of the impact reporting outcome findings in ESRD.
of the adequacy of dialysis on survival outcomes. A re-
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